Stock 9966 ALPHAMAB ONCOLOGY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alphamab Oncology

Equities

9966

KYG0330A1013

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-04-29 EDT 		5-day change 1st Jan Change
4.74 HKD +1.50% Intraday chart for Alphamab Oncology +16.46% -28.61%
04-10 Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting MT
04-10 Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 11,223 12,811 10,383 8,963 4,230 4,230 -
Enterprise Value (EV) 1 9,585 10,969 9,089 8,240 4,994 3,681 4,025
P/E ratio -13.5 x -29.8 x -25.2 x -27.3 x -27.4 x -14.2 x -11.2 x
Yield - - - - - - -
Capitalization / Revenue - - 71.1 x 53.7 x 26.6 x 17.2 x 12.3 x
EV / Revenue - - 62.2 x 49.4 x 22.8 x 14.9 x 11.7 x
EV / EBITDA -34.9 x -27.5 x -24.5 x -21.8 x -19.6 x -13.4 x -26 x
EV / FCF -24.3 x -25 x -19 x -19.2 x -9.76 x -12.8 x -11.7 x
FCF Yield -4.12% -3.99% -5.27% -5.22% -10.2% -7.8% -8.53%
Price to Book 2.77 x 5.64 x 5.55 x 5.75 x 2.78 x 3.08 x 3.28 x
Nbr of stocks (in thousands) 897,012 934,939 936,985 939,716 964,844 964,844 -
Reference price 2 12.51 13.70 11.08 9.538 4.384 4.384 4.384
Announcement Date 20-03-31 21-03-23 22-03-29 23-03-31 24-03-28 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - - 146 166.8 218.8 246.3 343.7
EBITDA 1 -274.3 -398.3 -370.7 -377.2 -254.2 -275.6 -154.9
EBIT 1 -284.7 -409.4 -415.6 -432.4 -323.3 -308.3 -203
Operating Margin - - -284.63% -259.15% -147.79% -125.2% -59.05%
Earnings before Tax (EBT) 1 -832.7 -427.8 -412.4 -325.7 -210.6 -298.8 -377.5
Net income 1 -832.7 -427.8 -412.4 -325.7 -210.6 -298.8 -377.5
Net margin - - -282.44% -195.22% -96.26% -121.33% -109.81%
EPS 2 -0.9280 -0.4600 -0.4400 -0.3500 -0.2200 -0.3097 -0.3912
Free Cash Flow 1 -395.2 -438 -478.7 -430 -360.4 -287.1 -343.3
FCF margin - - -327.84% -257.7% -161.61% -116.59% -99.87%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 20-03-31 21-03-23 22-03-29 23-03-31 24-03-28 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2
Net sales 1 44.9 - 146 - 113.3
EBITDA - - - - -
EBIT -190.2 -270.1 -145.5 - -
Operating Margin -423.73% - -99.67% - -
Earnings before Tax (EBT) 1 -324.7 -267.4 -145.1 - -178.4
Net income 1 -324.7 -267.4 -145.1 -147.3 -178.4
Net margin -723.12% - -99.34% - -157.5%
EPS -0.3500 -0.2900 - -0.1600 -
Dividend per Share - - - - -
Announcement Date 21-03-23 21-08-27 22-03-29 22-08-31 23-03-31
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - -
Net Cash position 1 1,638 1,841 1,294 724 829 549 206
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 -395 -438 -479 -430 -360 -287 -343
ROE (net income / shareholders' equity) -77.1% -18.2% -19.9% -19% -13% -19.6% -12.8%
ROA (Net income/ Total Assets) -45.2% -15.6% -15.4% -13.5% -9.9% -13.1% -15.2%
Assets 1 1,841 2,747 2,672 2,411 2,127 2,276 2,485
Book Value Per Share 2 4.520 2.430 2.000 1.660 1.580 1.420 1.340
Cash Flow per Share 2 -0.4200 -0.3700 -0.3400 -0.3200 -0.3400 -0.2600 -0.3200
Capex 1 170 90.8 158 130 37.8 36.6 37.3
Capex / Sales - - 108.29% 77.71% 16.94% 14.86% 10.85%
Announcement Date 20-03-31 21-03-23 22-03-29 23-03-31 24-03-28 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Alphamab Oncology

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
4.384 CNY
Average target price
4.211 CNY
Spread / Average Target
-3.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALPHAMAB ONCOLOGY Stock Alphamab Oncology
-28.61% 576M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 9966 Stock
  4. Financials Alphamab Oncology